ADX-629
ADX-629-MCD-001
Phase 2 small_molecule terminated
Quick answer
ADX-629 for Nephrotic Syndrome is a Phase 2 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aldeyra Therapeutics
- Indication
- Nephrotic Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated